Boothbay Fund Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Boothbay Fund Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-941,755	Closed	-$10.7M	–	2209
2023 Q2	$10.4M	Buy	941,755 +930,155	+8,019%	+$13M	0.23%	69
2023 Q1	$156K	Hold	11,600	–	–	﹤0.01%	1815
2022 Q4	$143K	Hold	11,600	–	–	﹤0.01%	1706
2022 Q3	$162K	Sell	11,600 -4,779	-29%	-$77K	﹤0.01%	1920
2022 Q2	$226K	Buy	+16,379	New	+$262K	0.01%	1657
2022 Q1	–	Sell	-20,294	Closed	-$331K	–	2629
2021 Q4	$331K	Buy	+20,294	New	+$342K	0.01%	1213

Boothbay Fund Management's ICPT Position: Q3 2023 in Review

Boothbay Fund Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2023, closing a stake of 941,755 shares — an estimated $10.7M sold.

Boothbay Fund Management first reported a position in ICPT in Q4 2021 and held it in 6 quarters. The position peaked at $10.4M in Q2 2023. 146 funds tracked by Wall St. Rank hold ICPT as of Q3 2023.

Boothbay Fund Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
Boothbay Fund Management sold 941,755 Intercept Pharmaceuticals, Inc. shares in Q3 2023, an estimated $10.7M.
Boothbay Fund Management first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2021 and held it in 6 quarters.
Boothbay Fund Management's Intercept Pharmaceuticals, Inc. position peaked at $10.4M in Q2 2023.
146 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2023.

Based on Boothbay Fund Management's 13F filing for Q3 2023, filed 14 Nov 2023.